Cytokinetics Inc
NASDAQ:CYTK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cytokinetics Inc
NASDAQ:CYTK
|
US |
|
N
|
Numis Corporation PLC
LSE:NUM
|
UK |
|
Elang Mahkota Teknologi Tbk PT
IDX:EMTK
|
ID |
|
Linea Directa Aseguradora SA Compania de Seguros y Reaseguros
MAD:LDA
|
ES |
|
P
|
Prosper Construction Holdings Ltd
HKEX:6816
|
HK |
|
S
|
Southern Copper Corp
DUS:PCU
|
US |
Cytokinetics Inc
Cytokinetics Inc., rooted firmly in the heart of California's biotechnology hub, has carved a niche in the complex arena of muscle biology. Founded in 1998, the company has focused its considerable expertise on the intricacies of muscle function, especially targeting conditions characterized by impaired muscle performance such as heart failure, ALS, and even SMA. Rather than pursuing the well-trodden paths of traditional pharmaceuticals, Cytokinetics delves into the uncharted realms of muscle contractility, leveraging its proprietary muscle biology expertise to develop small molecule therapeutics. Their pipeline is rich with candidates that promise to enhance muscle function, representing a blend of hope and scientific innovation for conditions that, until now, have seen few breakthroughs.
As a business, Cytokinetics operates at the confluence of innovative science and strategic partnerships. Financially, the company nurtures its pipeline through the judicious blend of equity financing, collaboration revenues, and milestone payments. Strategic alliances with larger pharmaceutical companies, such as collaborations previously established with Amgen and Astellas, play a pivotal role; these partnerships not only provide capital but also benefit from shared resources and expanded market reach. With therapies still largely in development, the company's revenue streams are intertwined with the success of clinical trials and approvals, rendering each scientific step a potential catalyst for investor interest and market value growth.
Cytokinetics Inc., rooted firmly in the heart of California's biotechnology hub, has carved a niche in the complex arena of muscle biology. Founded in 1998, the company has focused its considerable expertise on the intricacies of muscle function, especially targeting conditions characterized by impaired muscle performance such as heart failure, ALS, and even SMA. Rather than pursuing the well-trodden paths of traditional pharmaceuticals, Cytokinetics delves into the uncharted realms of muscle contractility, leveraging its proprietary muscle biology expertise to develop small molecule therapeutics. Their pipeline is rich with candidates that promise to enhance muscle function, representing a blend of hope and scientific innovation for conditions that, until now, have seen few breakthroughs.
As a business, Cytokinetics operates at the confluence of innovative science and strategic partnerships. Financially, the company nurtures its pipeline through the judicious blend of equity financing, collaboration revenues, and milestone payments. Strategic alliances with larger pharmaceutical companies, such as collaborations previously established with Amgen and Astellas, play a pivotal role; these partnerships not only provide capital but also benefit from shared resources and expanded market reach. With therapies still largely in development, the company's revenue streams are intertwined with the success of clinical trials and approvals, rendering each scientific step a potential catalyst for investor interest and market value growth.
Milestone Approvals: Myqorzo received FDA approval for obstructive HCM in the US, as well as approvals in China and the EU, marking Cytokinetics’ first drug from discovery to commercialization.
Initial Launch Progress: US launch of Myqorzo began immediately after approval, with strong early engagement from cardiologists and positive initial demand indicators.
Commercial Readiness: Over 700 HCPs became REMS-certified within three weeks, and more than 12,000 customer engagements were reported, reaching 95% of key prescribers.
Financial Health: Ended Q4 2025 with $1.22 billion in cash and equivalents; full-year 2025 revenue was $88 million, driven by technology transfer and milestones, with product sales to begin in Q1 2026.
2026 Guidance: No product sales guidance yet; combined R&D and SG&A expense expected at $830–870 million.
Pipeline Milestones: Key data from ACACIA-HCM trial in nonobstructive HCM on track for Q2 2026; launch in Germany expected in Q2; additional expected label and geographic expansions highlighted.
Analyst Q&A: Management addressed expectations for ACACIA-HCM trial endpoints, commercial uptake, and the early physician/patient response to Myqorzo.
